Praxis Precision Medicines (PRAX) is drawing attention after announcing positive topline results from its Essential3 trial for ulixacaltamide. The treatment met all primary endpoints and showed a strong safety profile, paving the way for the next regulatory steps.

Fresh momentum is clear in Praxis’s stock, with a jaw-dropping 234.66% 1-month share price return and a 128.86% jump year-to-date. While the shares took a breather with a recent dip, the 159.91% total shareholder return over the past year suggests investor confidence is building behind the Essential3 results and future milestones.

If breakthrough clinical news like this has you wondering what else is on the move, it could be the perfect time to broaden your investment radar and discover fast growing stocks with high insider ownership

With such rapid gains and analysts projecting significant upside, the key question now is whether Praxis Precision Medicines is still undervalued at current levels or if the market has already factored in much of the company’s growth potential.

Price-to-Book of 11.1x: Is it justified?

Praxis Precision Medicines trades at a price-to-book ratio of 11.1x, positioning the stock well above both peer and sector averages despite recent share price strength.

The price-to-book multiple compares the company’s market value to its net assets. It is often used for high-growth biotechs where profitability remains on the horizon. For Praxis, this signals the market’s willingness to pay a premium based on transformative clinical results and the promise of future pipeline progress, rather than tangible book value.

Praxis’s price-to-book ratio of 11.1x not only eclipses its peer group average of 10x, but also stands well above the US Biotechs industry norm of 2.5x. This level of optimism far outpaces the broader sector and indicates investors are assigning significant value to future expectations. If the market reverts to the industry multiple, significant price moves could follow.

Result: Price-to-Book of 11.1x (OVERVALUED)

However, rapid price gains could reverse if clinical milestones disappoint or if financial losses persist longer than the market currently anticipates.

Another View: Deep Discount to Fair Value?

Looking at Praxis through our SWS DCF model tells a very different story. According to this method, the shares are trading at a massive 90% discount to what our DCF calculates as fair value. Could the market be overlooking just how much upside remains?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Praxis Precision Medicines for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 843 undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Build Your Own Praxis Precision Medicines Narrative

If you think the numbers tell a different story, or want to dive deeper on your own terms, you can shape your own view in minutes and Do it your way

A great starting point for your Praxis Precision Medicines research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.

Looking for more investment ideas?

Unlock fresh opportunities and stay ahead by scanning the latest screens targeted at powerful trends. The right idea at the right moment makes all the difference.

• Boost your income potential by checking out these 18 dividend stocks with yields > 3% that consistently deliver yields above 3% and reward investors with robust payouts.
• Lead the charge in artificial intelligence by pinpointing tomorrow’s tech champions among these 26 AI penny stocks already attracting smart capital.
• Position yourself for value-driven gains as you size up these 843 undervalued stocks based on cash flows identified as prime bargains based on cash flow fundamentals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.